Gilead CEO Milligan, Chairman Martin to step down
Gilead Sciences Inc said on Wednesday that Chief Executive Officer John Milligan and Chairman John Martin will step down as soon as the end of the year, ending a nearly 30-year run at the U.S. biotech company for both men. Shares of Gilead, which also announced higher-than-expected second quarter profit, fell more than 1.6 percent in extended trading. It said the board is launching a search for a CEO to replace Milligan, who plans to leave at year-end.